Lexicon Pharmaceuticals
LXRX
104 hedge funds and large institutions have $354M invested in Lexicon Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 36 increasing their positions, 34 reducing their positions, and 14 closing their positions.
31% more call options, than puts
Call options by funds: $374K | Put options by funds: $286K
26% more capital invested
Capital invested by funds: $280M → $354M (+$74.1M)
7% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 14
6% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 34
0% more funds holding
Funds holding: 104 → 104 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.46% less ownership
Funds ownership: 77.61% → 77.15% (-0.46%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Axa
Paris,
France
|
+$769K |
| 2 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
+$582K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$269K |
| 4 |
Natixis Advisors
Boston,
Massachusetts
|
+$201K |
| 5 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
+$169K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$2.64M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.9M |
| 3 |
BlackRock
New York
|
-$448K |
| 4 |
Russell Investments Group
London,
United Kingdom
|
-$442K |
| 5 |
D.E. Shaw & Co
New York
|
-$314K |
LXRX Hedge Fund Activity: Q1 2023 in Review
104 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Lexicon Pharmaceuticals (LXRX) for Q1 2023, worth a combined $354M — up 26% from $280M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new LXRX positions and 14 closed out — a net gain of 1 holder — while 36 added to existing stakes and 34 trimmed.
The largest buyer was Axa, adding an estimated $769K. The largest seller was Millennium Management, cutting an estimated $2.64M.
- 104 institutional investors held Lexicon Pharmaceuticals (LXRX) as of Q1 2023, unchanged from Q4 2022.
- Funds reported $354M of Lexicon Pharmaceuticals stock for Q1 2023, up 26% quarter-over-quarter.
- 15 funds opened new Lexicon Pharmaceuticals positions in Q1 2023 and 14 closed out, a net change of +1 holder.
- The largest Lexicon Pharmaceuticals buyer in Q1 2023 was Axa, an estimated $769K added.
- The largest Lexicon Pharmaceuticals seller in Q1 2023 was Millennium Management, an estimated $2.64M sold.
Based on aggregated 13F filings for Q1 2023.